Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0026986 (myelodysplastic syndrome)
 14,926 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Adenylate-kinase (AK) interacts in the balance of phosphate acceptors and donators. With respect to the polymorphism of enzyms of erythrocytes there can be assumed a system of two co-dominate allels determined by the genotype of AK 1 and AK 2 with the phenotypes of AK 1-1, AK 2-1 and AK 2-2. The distribution of AK within 108 cases of MDS and 90 controls was examined. AK 2-1 was found in about 30% of bipolar MDS, but in no case of unipolar MDS or controls. The possible relations were discussed demonstrating a synopsis of the pathogenesis of MDS.
 ...
PMID:[Adenylat-kinase-Systeme, ein Beitrag zum manisch-depressiven Kranksein (MDK)]. 18 95

Using a Toshiba GC-401 gamma camera with MDS computer Trinary a new method was developed for subtracting the extrarenal (extracanalicular) "background" from the count rate recorded over the kidneys after intravenous administration of 131I-hippurate. Mean subtraction factors of the "blood" activity curve were calculated from a study of 27 patients who were given 51Cr-HSA for purposes of conventional renography with "background" subtraction. The values of the mean subtraction factors FR,L for the right and left kidney, by which a blood count rate should be multiplied amounted to 0.86 +/- 0.12 and 0.79 +/- 0.13, respectively. A comparison of the coefficients of variation of the pure renal signal when mean vs. individually determined subtraction factors were used, and the verification of the method in unilaterally nephrectomized patients have demonstrated that determination of the factors, FR,L, for each patient individually is not required and sufficient precision can be obtained by using the method and factors reported in this study.
 ...
PMID:A method for subtraction of the extrarenal "background" in dynamic 131I-hippurate renoscintigraphy. 37 22

A method is discussed and illustrated which yields a geometric representation of asymmetric proximity matrices. Assuming the observations are metric the data matrix is uniquely decomposed into a symmetric and a skew-symmetric matrix-valued component. The former entails a spatial configuration vis some MDS technique; the formation contained in the latter can then be integrated into this space in various ways.
 ...
PMID:[A procedure for analyzing metric asymmetric proximity matrices (author's transl)]. 54 96

The purpose of the present study is to investigate the structure of visual similarity. Stimuli were two series of geometric figures, one of them was 16 rectangles (series A) and the other 18 "apparent" cubes (series B). Each stimulus series was given to eleven adults and eleven infants (five years old). Kruskal's nonmetric MDS was applied to observed (subjects mean average) similarity data. The main results were as follows: (a) The Euclidean model was more suited to the data than the city block model. (b) The number of necessary dimensions was two (series A), or three (series B) in both groups of the subjects.
 ...
PMID:[On the structure of visual similarity (author's transl)]. 67 70

A method for quantitative gas chromatographic determination of plasma lipids (free cholesterol, cholesteryl esters and triglycerides) in the low concentration range is described. This method permits a determination of not only the lipid classes mentioned above, but also their fractions according to molecular weight, down to 10 ng, without previous derivatization. Special attention was devoted to the preparation of columns with high efficiency and minimal losses of the test substances. The best results were obtained with a glass column 0.5 m x 2.0 mm I.D., packed with 1% OV-1 on Gas-Chrom Q (100--120 mesh). The processing of results is fully automated, using an MDS-2400 computer and includes the calculation of a non-linear calibration plot for each substance analyzed, accuracy control of the measured values, tabulation of the fwr values and the calculation for analyses of biological samples. For the calibration, the pure substances were used at 15 concentrations within a range of 10--1000 ng. The coefficient of variation calculated from 20 duplicate measurements of the calibration mixture did not exceed 5% for any component in the interval from 10 to 100 ng or 3% within range from 100 to 1000 ng.
 ...
PMID:Automated quantitative gas--liquid chromatography of intact lipids. I. Preparation and calibration of the column. 70 23

In a retrospective study we investigated the development of HLA antibodies in patients who received platelet concentrates from cell separators. 118 hematological/oncological patients from the Frankfurt University Clinics were investigated. They received between 4 and 66 platelet concentrates for the duration of 30 months. All patients had a negative antibody screening on admission. 31% developed either transient (15%) or permanent (16%) lymphocytotoxic antibodies. The increasing number of platelet transfusions did not correlate with the development of HLA antibodies, but the appearance of these antibodies seemed to be dependent on the disease. Permanent antibodies appeared in 8% of patients with acute leukemia, whereas 38% of patients suffering from CL, lymphoma, MDS and myeloma produced antibodies. Some patients (18) received granulocyte transfusions as well. It is striking that 11% of these patients developed permanent and 28% transient HLA antibodies. There exist no data about recent transfusions or previous pregnancies. To lower the rate of sensitization in patients with diseases such as CL, lymphoma, MDS and myeloma, it should be discussed whether leukocyte-depleted platelet concentrates should be given to these patients.
 ...
PMID:[Development of HLA antibodies in thrombocyte substitution with cell separator products]. 128 49

Granulocyte colony-stimulating factor (G-CSF) has strong leukopoietic activity and it is used for patients with leukopenia during leukemia chemotherapy. However, some leukemia cells show a high affinity to G-CSF and are driven to proliferative phase. In our laboratory, we developed two testing methods. 1) Flow cytometric method on G-CSF susceptibility of leukemia cells using FITC-labeled G-CSF, and 2) Immunohistochemical method for detecting the ratio of cells driven from dormant phase to proliferative phase by G-CSF with anti-PCNA antibody and Ki-67 antibody. In MDS patients G-CSF administration induced an increase of cells in proliferative phase. The patients treated with cytosine arabinoside following G-CSF showed hematologically good improvement. A new mode of therapy using G-CSF in combination with other cytokines or antileukemic agents will be developed in the near future for treatment of leukemia patients.
 ...
PMID:[Recent trend in G-CSF therapy and clinical laboratory tests]. 128 10

A 40-year-old man was admitted with high fever and cough. Pneumonic shadows of the left middle and lower lung fields increased rapidly, and his blood gases worsened. Initial treatment with cefmenoxime, piperacillin, and minocycline was ineffective. Administration of rifampicin was started for suspected legionella pneumonia, but it did not control the spread of the pneumonia shadows. After addition of an antifungal agent and trimethoprim-sulfamethoxazole, his symptoms gradually improved. Isolation of Legionella pneumophila from sputum specimens collected on the 4th day of admission confirmed the diagnosis on day 10. The patient was then given oral rifampicin plus cefmenoxime to prevent mixed infection, and showed a satisfactory improvement. Legionella pneumonia developed secondary to compromise of the patient's immunity due to steroid therapy for MDS. After recovering from Legionella pneumonia, the patient subsequently developed tuberculous pleurisy and Pneumocystis carinii pneumonia, which were cured by antituberculous therapy and trimethoprim-sulfamethoxazole. However, acute hepatitis followed by hepatic failure developed, and he died on day 121 after admission.
 ...
PMID:[A case of Legionella pneumonia with myelodysplastic syndrome]. 128 32

According to the FAB classification, a patient (case 1) could not be diagnosed as MDS-RA, although she had clinical features of MDS, as compared with another patient (case 2) who was diagnosed as RAS and had abnormal karyotype (20q- and 5q-) of bone marrow (BM) cells. BM cells of the two patients were SCD (sister chromatid differentiation) negative. Rearrangement of c-erbB and c-erbA was found in the genome of the BM cells in both patients, when southern blot hybridization was performed with probe v-erbB+A. Therefore, case 1 could be diagnosed as preleukemia. During a period about 3 years of treatment with the drug stanozolol in case 1 there was good effect and successful reversion was obtained. She had then normal hematologic and cytogenetic patterns of BM and PB and the rearrangement of c-erbB of BM cells also disappeared. She has worked for two years since then. The mechanism of effective treatment and successful reversion was discussed briefly. Probe v-erbB was shown to be useful in investigation of gene diagnosis of preleukemia or MDS (shown elsewhere).
 ...
PMID:[Gene diagnosis and successful reversion in a patient with preleukemia]. 130 46

Material from 63 cases with primary myelodysplastic syndromes (P-MDS) (French-American-British [FAB] types: refractory anemia [RA] = 21; RA with ring sideroblasts [RARS] = 8; RA with excess of blasts (RAEB) = 10; RAEB in transformation (RAEBt) = 6; chronic myelomonocytic leukemia [CMML] = 10 and unclassifiable = 8, ie, bone marrow aspiration was inadequate and stringent FAB criteria were not applicable) was analyzed for bone marrow histologic and immunohistochemical patterns. Standard Giemsa, hematoxylin and eosin (H&E) and reticulin stains were used for morphologic assessment. To identify the cell lineage precisely, chloroacetate esterase staining and an indirect immunoperoxidase technique using mouse monoclonal antibodies CD15, CD68, HLA-DR, and rabbit polyclonal CD3 and UEA-1 (lectin) was developed on formalin-fixed paraffin embedded bone marrow biopsies (BMB). The immunohistochemical assessment permitted accurate identification of dysplastic features such as mononuclear and binuclear megakaryocytes, Pelger-Huet neutrophils, and binuclear erythroblasts. Additional bone marrow histologic and immunohistochemical features observed were heterogeneity of immunohistochemical staining in various cell lineages, megakaryocytic emperipolesis, alteration of bone marrow microarchitecture, intravascular clusters of hematopoietic cells, and the types of benign lymphoid aggregates. The nature of abnormally localized immature precursors (ALIP) was discerned. Three types of clusters of immature cells were found that were difficult to distinguish on Giemsa and H&E morphology, these were erythroid aggregates (n = 18); megakaryocytic aggregates (n = 4), and immature granulocytic and monocytic aggregates (n = 32). The bone marrow histologic and immunohistologic patterns permitted the identification of four groups of clinical relevance: Group 1, cases with predominant erythroid hyperplasia and without ALIP (n = 15); group 2, cases with prominent myeloid hyperplasia and presence of ALIP (n = 32); group 3, cases with hypoplastic MDS (n = 10); and group 4, cases with hyperfibrotic MDS (n = 6). Statistical analysis showed a significant difference in survival and leukemic transformation between groups 1, 2, 3, and 4, with cases in group 2 showing the worst prognosis with early death due to increased propensity to leukemic transformation and cytopenia-related complications (P less than .0001). We conclude that immunohistochemistry is feasible on routinely processed BMB and the information obtained is of diagnostic and prognostic importance in P-MDS. The phenotype of ALIP varies with the morphologic and histologic subtypes of MDS and the term should be reserved for cases in whom the clusters in the intertrabecular region are of myeloid (granulocytic and monocytic) lineage on immunohistochemistry.
 ...
PMID:Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies. 137 Feb 3


1 2 3 4 5 6 7 8 9 10 Next >>